Confo

Confo Therapeutics is a clinical-stage biotech company headquartered in Ghent, Belgium, spun out of Professor Jan Steyaert's lab at VUB and VIB. Its proprietary ConfoBody technology uses single-domain VHH antibodies to lock G protein-coupled receptors (GPCRs) in pharmacologically relevant conformations, enabling discovery of small molecule and antibody-based therapeutics for class A and B GPCR targets, including previously undruggable ones. The company has forged drug discovery collaborations with major pharma partners including Eli Lilly, Roche, Daiichi Sankyo, Lundbeck, Regeneron, and AbCellera, and focuses its pipeline on endocrine and metabolic diseases.